48 results on '"Kohli, Harbir Singh"'
Search Results
2. Impact of COVID-19 Pandemic on Nephrology Training in an Academic Center in India: Looking Forward Through Online Teaching.
- Author
-
Bharati, Joyita and Kohli, Harbir Singh
- Subjects
- *
ONLINE education , *ACADEMIC medical centers , *BIOPSY , *NEPHROLOGY , *HEALTH care reform , *CONTINUUM of care , *COMPARATIVE studies , *QUESTIONNAIRES , *SCALE analysis (Psychology) , *DESCRIPTIVE statistics , *MANAGEMENT , *COVID-19 pandemic , *MEDICAL education - Published
- 2021
- Full Text
- View/download PDF
3. Endothelial nitric oxide synthase gene polymorphisms and renal responsiveness to RAS inhibition therapy in type 2 diabetic Asian Indians
- Author
-
Cheema, Balneek Singh, kohli, Harbir Singh, Sharma, Rajni, Bhansali, Anil, and Khullar, Madhu
- Subjects
- *
ENDOTHELIAL cells , *NITRIC-oxide synthases , *GENETIC polymorphisms , *SINGLE nucleotide polymorphisms , *TYPE 2 diabetes , *DISEASES , *INDIANS (Asians) - Abstract
Abstract: Aim: To investigate the association of functional single nucleotide polymorphisms (SNPs) of the endothelial nitric oxide synthase gene (eNOS) gene (T-786C, G894T) and one variable number tandem repeat polymorphism (aa 27VNTR bb) with reno-protective response to angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) therapy in North Indian type 2 diabetic mellitus (T2DM) subjects with cases having diabetic nephropathy (DN) and controls without DN. Method: We genotyped three polymorphisms of eNOS (two SNPs: T-786C, G894T and one 27 VNTR) in T2DM patients with overt nephropathy (cases: n =320) and T2DM patients without overt nephropathy (controls: n =490), using validated PCR-RFLP assays. These 810 North Indian T2DM patients treated with ACEI or ARB after diagnosis were followed up for 3 years. Percent changes in eGFR, urinary albumin excretion (UAE), serum creatinine at the end of 3 years of treatment were taken as end points of renoprotective response. Result: We observed that in normoalbuminuric patients, eNOS -786 CC genotype and haplotypes C-b-G and C-b-T were associated with lesser renoprotective response to ACEI. While, in macroalbuminurics, eNOS -786 CC genotype, haplotypes C-b-G and C-b-T and 27VNTR aa were associated with better renoprotective response to ACEI/ARB. Conclusion: Our results showed that eNOS T-786C CC genotype and 27VNTR individually and in interaction with other eNOS SNPs modulate renoprotective efficacy of ACEI and ARB in T2DM patients, depending on the status of proteinuria. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
4. Lipid Peroxidation Products Formation with Various Intravenous Iron Preparations in Chronic Kidney Disease.
- Author
-
Ganguli, Anirban, Kohli, Harbir Singh, Khullar, Madhu, Lal Gupta, Krishan, Jha, Vivekanand, and Sakhuja, Vinay
- Subjects
- *
THERAPEUTIC use of iron , *KIDNEY diseases , *LIPIDS , *OXIDATIVE stress , *MALONDIALDEHYDE , *INTRAVENOUS catheterization - Abstract
The role of intravenous iron in contributing to oxidative stress and endothelial dysfunction in chronic kidney disease (CKD) is debatable. The present study assessed differences in fasting plasma malondialdehyde (pMDA) levels 30 minutes before and after intravenous infusion of low molecular weight iron dextran (ID) (n = 19), iron-sucrose (IS) (n = 20), and sodium ferrigluconate complex (SFGC) (n = 20) in stage 3 and 4 CKD patients. Post-infusion pMDA levels were significantly raised with respect to baseline (p < 0.001). pMDA was significantly higher in the SFGC group vs. IS (3.02 ± 0.84 μmol/L vs. 2.82 ± 0.44 μmol/L, p = 0.034) or SFGC vs. ID (3.02 ± 0.84 μmol/L vs. 2.92 ± 0.20 μmol/L, p = 0.048). There was no difference between IS vs. ID (2.82 ± 0.44 μmol/L vs. 2.92 ± 0.20 μmol/L, p = 0.21). To conclude, all forms of parenteral iron, especially SFGC, significantly raise pMDA levels in the immediate post-transfusion period. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
5. Predictors of Mortality in Acute Renal Failure in a Developing Country: A Prospective Study.
- Author
-
Kohli, Harbir Singh, Bhat, Ashok, Jairam, A., Aravindan, A.N., Sud, Kamal, Jha, Vivekanand, Gupta, Kishan Lal, and Sakhuja, Vinay
- Subjects
- *
ACUTE kidney failure , *MORTALITY , *KIDNEY diseases , *DISEASE complications ,DEVELOPING countries - Abstract
Acute renal failure (ARF) occurs in wide range of conditions, making the evaluation of its prognosis a difficult task. Data regarding prognostic factors in ARF in a general population in developing countries are scarce. The objective of the study was to describe predictors of mortality in ARF that are relevant in the developing world. This prospective study was carried out over a one-year period; all hospitalized adults with ARF were included in the study. Predictors of mortality studied included causes of ARF, pre-existing diseases, and severity as well as complications of ARF. Of 33,301 patients admitted during the study period, 294 (0.88%) were either admitted with or developed ARF after hospitalization. Mean age was 43.9 ± 16.9 (18-86 yrs). Sepsis was the most common cause (63.26%). Pre-existing diseases like cardiovascular disease (CVSD), respiratory system disease (RSD), central nervous system disease (CNSD), hypertension, diabetet mellitus (DM), and malignancy were significantly higher in elderly as compared to younger patients. On univariate analysis sepsis, hypoperfusion as a cause of ARF and hospital-acquired ARF were associated with higher mortality. Pre-existing diseases viz. RSD, CVSD, CNSD, and DM had higher mortality. Among the severity and complications of ARF, oliguria, bleeding and infection during the course of ARF and critical illness were predictors of poor outcome. Age >60 yrs was associated with significantly higher mortality. However, on multivariate analysis, only critical illness (odds ratio 37.3), age > 60 years (odds ratio of 5.6), and sepsis as cause of ARF (odds ratio of 2.6) were found to be independent predictors of mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
6. Memory B cells predict outcome in primary podocytopathies of adults.
- Author
-
Bharati, Joyita, Das, Jhumki, Vignesh, Pandiarajan, Jhaveri, Kenar D, Prabhahar, Arun, Das, Chandan Krushna, Parihar, Anita Singh, Nada, Ritambhra, Ramachandran, Raja, Rawat, Amit, and Kohli, Harbir Singh
- Subjects
- *
IMMUNOLOGIC memory , *FOCAL segmental glomerulosclerosis , *B cells , *NEPHROTIC syndrome , *ADULTS , *AUTOBIOGRAPHICAL memory - Abstract
This article examines the role of B cells in the development and treatment of primary podocytopathies, specifically minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). The study focuses on adults with new-onset nephrotic syndrome (NS) caused by primary podocytopathy and compares them to healthy controls. The findings indicate that B cell proportions differ between children and adults, and specific B cell subsets are associated with disease activity and predict response to steroid treatment. These findings have implications for targeted therapies for primary podocytopathies. However, more research is needed to confirm these results. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
7. Circulating "Neutrophils extra-cellular traps" during the early post-renal transplant period and correlation with graft dysfunction and rejection.
- Author
-
Kumar, Mahendra, Kenwar, Deepesh B., Sekar, Aravind, Singh, Jagdeep, Nada, Ritambhra, Saikia, Biman, Sharma, Ashish, Kohli, Harbir Singh, Anand, Shashi, and Minz, Ranjana W.
- Subjects
- *
GRAFT rejection , *NEUTROPHILS , *REPERFUSION injury , *KIDNEY transplantation , *EPITHELIAL-mesenchymal transition , *ALLOIMMUNITY , *CIRCULATING tumor DNA - Abstract
Background: Neutrophil extracellular traps (NETs) have a role in infection, autoimmunity, autoinflammation, thrombosis, ischemia-reperfusion injury (IRI), epithelial-mesenchymal transition, vasculitis, and metabolic diseases. However, its role in early graft injury and graft outcome has not been elucidated till now. We evaluated the circulating NETs during early post-transplant periods and their correlation with graft outcome and IRI. Methods: Prospectively, thirty kidney transplants recipient (KTR) were recruited and grouped into non-dysfunction (Group-A) and dysfunction groups (Group-B). Serum levels of circulating NETs were estimated by measuring myeloperoxidase-DNA complex at three-time points: pre-transplant, 8 h post-transplant, and 18 h post-transplant; and correlated with early graft outcome. Malondialdehyde (MDA), a marker of oxidative stress or IRI, was also measured to assess its relation with NETs and early graft outcome. Results: Circulating NETs were significantly increased in both non-dysfunctional [Median OD: 0.11 (0.01-0.19) to 0.51 (0.22-0.91); p = 0.001] and dysfunctional [Median OD: 0.16 (0.12-0.27) to 0.38 (0.19-0.68); p = 0.047] KTR during first 8 h of transplant followed by fall at 18 h post-transplant [0.25 (0.18-0.72) and 0.35 (0.26-0.36) respectively]; however, no significant difference were observed between two groups at any time points. Isolated biopsy-proven graft rejection KTR also had higher circulating NETs during the early post-transplant period [Median OD: 0.16 (0.13-0.31) to 0.38 (0.28-1.5); p > 0.05] but no significant difference compared to non-dysfunctional KTR. MDA also displayed similar trends with an early significant rise [9.30 (7.74-12.56) µM to 17.37 (9.11-22.25) µM; p = 0.03 in group-A, and 8.7 (6.04-10.30) µM to 14.66 (13.39-21.63) µM; p = 0.01in group-B] followed by fall at 18 h in both groups [10.21 (7.64-13.90) µM and 11.11 (9.15-17.54) µM respectively]. Despite similar trends of both NETs and MDA, there was no significant correlation between these; however, creatinine exhibits a significant inverse correlation with NETs and MDA both. Conclusion: Circulating NETs are significantly increased during the early post-transplant period in KTR irrespective of early graft outcome. Similar dynamics of MDA indicate that the early rise of NETs might be a part of IRI. However, molecular studies with large sample sizes and longer follow up are required to reach more defined conclusions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Angiotensin-converting enzyme gene variants interact with the renin-angiotensin system pathway to confer risk and protection against type 2 diabetic retinopathy.
- Author
-
Cheema, Balneek Singh, Kohli, Harbir Singh, Sharma, Rajni, Shah, Viral N., Bhansali, Anil, and Khullar, Madhu
- Subjects
- *
ANGIOTENSIN converting enzyme , *TYPE 2 diabetes , *DIABETIC retinopathy , *META-analysis , *FLUORESCENCE angiography - Abstract
The article presents a study which examines the possible interaction of angiotensin-converting enzyme (ACE) gene variants with renin-angiotensin system (RAS) pathway and the and progression of type 2 diabetic retinopathy (DR). The study conducted meta-analysis and retinal photography or fluorescein angiography tests among 2,224 Chinese DR patients. Results revealed that increased expression of ACE/AGT confer risk and protection against type 2 DR which is associated with retinal RAS.
- Published
- 2013
- Full Text
- View/download PDF
9. Long-term complications in patients with childhood-onset nephrotic syndrome.
- Author
-
Bharati, Joyita, Tiewsoh, Karalanglin, Dawman, Lesa, Singh, Tarvinder, Gorsi, Ujjwal, Rajarajen, Arun Prabhahar, Sharma, Aakanksha, Chanchlani, Rahul, Ramachandran, Raja, and Kohli, Harbir Singh
- Subjects
- *
NEPHROTIC syndrome diagnosis , *OBESITY , *HYPERTENSION , *SCIENTIFIC observation , *CAROTID intima-media thickness , *NEPHROTIC syndrome , *CHILD development , *HEALTH status indicators , *TERTIARY care , *IMMUNOSUPPRESSION , *CARDIOVASCULAR system , *AGE factors in disease , *DESCRIPTIVE statistics , *BONE density , *DATA analysis software , *DISEASE remission , *GROWTH disorders , *DISEASE complications , *CHILDREN - Abstract
Background: Reports on long-term complications of childhood-onset nephrotic syndrome (NS), such as obesity, osteoporosis, growth failure, and hypertension, are mostly from developed countries not representing South Asian ethnicities. Furthermore, data on cardiovascular health among patients with childhood-onset NS are limited. Methods: This was an observational study involving patients attending a tertiary care center. Patients aged 15 years and older were examined for long-term complications and remission of NS at their visit in December 2021. Childhood-onset NS meant onset of NS before 10 years of age. Long-term complications included obesity, growth failure, low bone mineral density (BMD) Z score, hypertension, and increased carotid intima-media thickness (cIMT). Long-term remission was defined as no relapse for the last ≥ 3 consecutive years without immunosuppressive medication to maintain remission. Results: Of 101 patients studied (~ 80% with frequent relapsing (FR)/steroid-dependent (SD) NS), the mean age was 17.6 (± 2.4) years at the time of study. Long-term complications were noted in 89.1% of patients which included one or more of the following: obesity (22.7%), growth failure (31.7%), low BMD Z score (53.5%), hypertension (31.7%), and high cIMT (50.5%). Thirty-nine patients (38.6%) were in long-term remission at the time of the study. Growth failure and low BMD Z scores were less frequent in patients with long-term remission compared to those without long-term remission. Conclusions: In patients with childhood-onset NS (predominantly FR/SDNS) who were studied at ≥ 15 years of age, ~ 90% had long-term complications which included high cIMT in 50%. Only ~ 40% were in long-term remission. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Bilateral Renal Cortical Necrosis in a Case of Granulomatosis with Polyangitis.
- Author
-
Sethi, Jasmine, Nada, Ritambhra, Kohli, Harbir Singh, and Gupta, Krishan Lal
- Subjects
- *
BIOPSY , *CHEST X rays , *CREATININE , *DYSPNEA , *ENZYME-linked immunosorbent assay , *FEVER , *FLUORESCENT antibody technique , *KIDNEYS , *KIDNEY diseases , *LUNG surgery , *MICROSCOPY , *OLIGURIA , *PHOTOGRAPHY , *STEROIDS , *POSITRON emission tomography , *URINALYSIS , *COMORBIDITY , *WEGENER'S granulomatosis , *CYCLOPHOSPHAMIDE , *AZATHIOPRINE , *METHYLPREDNISOLONE , *ANTINEUTROPHIL cytoplasmic antibodies - Published
- 2019
- Full Text
- View/download PDF
11. A randomized trial of once daily versus twice daily dosing of oral iron in CKD.
- Author
-
Sood, Vivek, Kamboj, Kajal, Bhatia, Prateek, Sharma, Vishal, Kundu, Monica, Ghosh, Arpita, Singh, Sanjay Kumar, Sen, Thakur, Kaur, Prabhjot, Ramachandran, Raja, Rathi, Manish, Kohli, Harbir Singh, Gupta, Krishan Lal, Malhotra, Samir, Yadav, Ashok Kumar, Kumar, Vivek, and Jha, Vivekanand
- Subjects
- *
TRANSFERRIN , *IRON , *FERRITIN , *IRON in the body , *CHRONIC kidney failure , *CLINICAL trials - Abstract
We investigated the effect of two dosing regimens of oral iron on iron status and hematological parameters in patients with CKD. In this single center, open label, randomized, active controlled clinical trial, stable adult patients with CKD stage G3–4 with percentage transferrin saturation (%TSAT) ≤ 30% and serum ferritin ≤ 500 ng/ml were eligible. Participants were randomized to receive either 100 mg of ferrous ascorbate once daily (OD group) or 100 mg of ferrous ascorbate twice daily (BD group, total daily dose 200 mg). The primary outcome was change in %TSAT between groups over 12 weeks. The secondary outcomes were changes in other iron status and hematological parameters, serum interleukin-6 (IL-6) and hepcidin. 80 participants were enrolled out of which 76 completed the study. Change in %TSAT was not significantly different between groups (β = − 1.43, 95% CI − 3.99 to 1.12, BD group as reference). The rise in serum ferritin was less in the OD group as compared to BD group (β = − 0.36, 95% CI − 0.61 to − 0.10) whereas MCHC increased in the OD group as compared to decrease in the BD group (β = 0.37, 95% CI 0.067–0.67). These observations need exploration to ascertain the impact of different oral iron dosing strategies in CKD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Novel Flow Cytometry-Based Method for Detection of Anti-HLA Complement Activating Donor-Specific Antibodies in Renal Transplant Recipients and Its Comparison With Other Conventional Detection Methods.
- Author
-
Rani, Lekha, Singh, Heera, Saikia, Biman, Aggarwal, Ritu, Kumar, Yashwant, Kumar, Mahendra, Chhabra, Seema, Kumar, Manoj, Kumar, Bhuvnesh, Kumar, Vinkesh, Das, Prabir, Sharma, Ashish, Ramchandran, Raja, Kohli, Harbir Singh, and Minz, Ranjana Walker
- Subjects
- *
KIDNEY transplantation , *IMMUNOGLOBULINS , *BINDING site assay , *B cells , *T cells - Abstract
Presence of preformed donor specific antibodies (DSAs) detected by complement-dependent cytotoxicity (CDC-XM) is a strong contraindication for transplant. However, it has limitations including its sensitivity and its inability to distinguish between HLA-specific and other non-HLA-specific antibodies. In this study, we standardized CDC-XM by flow cytometry and determined its relevance by comparing its results with other methods of DSA detection, such as routine CDC-XM, antibody binding assay by flow cytometry (FC-XM), and Luminex-based crossmatch assays, such as Luminex crossmatch (LXM) and virtual crossmatch (VXM). A total of 79 serum samples were tested for DSAs by the flow cytometric complement-dependent cytotoxicity crossmatch assay (FC-CDC-XM) and then the results of FC-CDC-XM were compared with other detection methods such as CDC-XM, FC-XM, LXM, and VXM. We found that the FC-CDC-XM assay is more sensitive than routine CDC-XM. Out of total 79 sera, 24 sera were detected positive (T cells positive: 1 case and B cells positive: 23) by FC-CDC-XM as compared with 3 sera using CDC-XM; these 3 sera also showed positivity by FC-CDC-XM. After FC-XM assay, 23 samples were positive by FC-XM and out of these 23 samples, 13 were also positive by FC-CDC-XM. On comparing the FC-CDC-XM results with VXM and LXM, 10 sera of 24 FC-CDC-XM positive had HLA class II antibodies detected on a Luminex platform. The FC-CDC-XM is a more sensitive and specific method for detection of HLA-specific complement-fixing antibodies than CDC-XM and FC-XM. FC-CDC-XM should be used in tissue-typing laboratories after intra- and inter- laboratory validation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Successful management of severe hyponatremia in CKD‐VD: In a cost limited setting.
- Author
-
Pattanashetti, Navin, Bharati, Joyita, Kohli, Harbir Singh, Gupta, Krishan Lal, and Ramachandran, Raja
- Subjects
- *
HYPONATREMIA , *CHRONIC kidney failure , *BLOOD flow , *AZOTEMIA , *HEMODIALYSIS , *SODIUM metabolism - Abstract
Patients with end stage renal disease (ESRD) and severe hyponatremia always pose a challenge to manage. It is necessary to correct biochemical parameters, advanced azotemia, and fluid overload with conventional haemodialysis (HD) but it may correct serum sodium (Na) rapidly resulting in neurological complications like seizures and osmotic demyelination syndrome. Continuous renal replacement therapy (CRRT) is an ideal modality to manage such patients. However, most of the centers in the developing or underdeveloped nations do not have CRRT facility. We present two cases of ESRD, who had advanced azotemia requiring dialysis, also had persistent vomiting and severe hyponatremia (one with Na 107, another with Na 109 mEq/L), both cases were managed with conventional HD using dialysate Na concentration of 128 mEq/L (lowest permissible level of Na in a traditional HD machine) and keeping the blood flow of 50 mL/min. The serum Na increased by 1 mEq/L/h during first HD session, during the next session blood flow increased to 100 mL/min, and serum Na increased by two mEq/L/h. At the end of 48 hours, we were able to successfully correct serum Na by 18 mEq/L, with complete resolution of uremic manifestations and no neurological deficits. The current reports highlight management of hyponatremia in newly diagnosed ESRD in a cost limited setting. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Serum myo-inositol oxygenase levels at hospital discharge predict progression to chronic kidney disease in community-acquired acute kidney injury.
- Author
-
Kakkanattu, Tom Jose, Kaur, Jaskiran, Nagesh, Vinod, Kundu, Monica, Kamboj, Kajal, Kaur, Prabhjot, Sethi, Jasmine, Kohli, Harbir Singh, Gupta, Kishan Lal, Ghosh, Arpita, Kumar, Vivek, Yadav, Ashok Kumar, and Jha, Vivekanand
- Subjects
- *
ACUTE kidney failure , *CHRONIC kidney failure , *HOSPITAL admission & discharge , *LIPOCALIN-2 , *ACUTE diseases - Abstract
Acute kidney injury (AKI) increases the risk of morbidity, mortality, and progression to chronic kidney disease (CKD). There are few data on the risk of CKD following community-acquired AKI (CA-AKI) and its predictors from developing countries. We evaluated the association of a panel of serum and urine biomarkers at the time of hospital discharge with 4-month renal outcome in CA-AKI. Patients of either sex, aged between 18 and 70 years, with no underlying CKD, and with CA-AKI were recruited at the time of discharge from hospital in this prospective observational study. Levels of serum and urine biomarkers were analyzed and association between these markers and development of CKD, defined as eGFR < 60 ml/min/1.73 m2 or dialysis dependence at 4 month after discharge, were analyzed using multivariate logistic regression analysis and penalized least absolute shrinkage and selection operator logistic regression. Out of a total 126 patients followed up for 4 months, 25 developed CKD. Those who developed CKD were older (p = 0.008), had higher serum creatinine (p < 0.001) and lower serum albumin (p = 0.001) at discharge. Adjusted logistic regression showed that each 10% increase in standardized serum myo-inositol oxygenase (MIOX) level increased the odds of progression to CKD by 13.5%. With 10% increase in standardized urine Neutrophil gelatinase-associated lipocalin (NGAL), serum creatinine and urine protein creatinine ratio (uPCR), increase in the odds of progression to CKD was 10.5%, 9.6% and 8%, respectively. Multivariable logistic model including serum MIOX, discharge serum creatinine and discharge uPCR, was able to predict the progression of CKD [AUC ROC 0.88; (95% CI 0.81, 0.95)]. High level serum MIOX levels at the time of discharge from hospital are associated with progression to CKD in patients with CA-AKI. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review.
- Author
-
Prabhahar, Arun, Naidu, G. S. R. S. N. K., Chauhan, Prabhat, Sekar, Aravind, Sharma, Aman, Sharma, Alok, Kumar, Asheesh, Nada, Ritambhra, Rathi, Manish, Kohli, Harbir Singh, and Ramachandran, Raja
- Subjects
- *
COVID-19 , *ANTINEUTROPHIL cytoplasmic antibodies , *VACCINATION , *VASCULITIS , *DISEASE incidence , *AUTOIMMUNE diseases , *LEUKOCYTOCLASTIC vasculitis - Abstract
For the foreseeable future, vaccines are the cornerstone in the global campaign against the Coronavirus Disease-19 (COVID-19) pandemic. As the number and fatalities due to COVID-19 decline and the lockdown anywise rescinded, we recognize an increase in the incidence of autoimmune disease post-COVID-19 vaccination. However, the causality of the most vaccine-induced side effects is debatable and, at best, limited to a temporal correlation. We herein report a case of a 51-year-old gentleman who developed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) 2 week post-COVID-19 vaccination. The patient responded favorably to oral steroids and rituximab. Additionally, we conducted a case-based review of vaccine-associated AAV describing their clinical manifestations and treatment response of this emerging entity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Peritoneal dialysis–first initiative in India: a cost-effectiveness analysis.
- Author
-
Gupta, Dharna, Jyani, Gaurav, Ramachandran, Raja, Bahuguna, Pankaj, Ameel, Mohammed, Dahiya, Bharat Bhushan, Kohli, Harbir Singh, Prinja, Shankar, and Jha, Vivekanand
- Subjects
- *
RENAL replacement therapy , *PERITONEAL dialysis , *COST effectiveness , *QUALITY-adjusted life years , *BLOODBORNE infections , *DRUG prices - Abstract
Background The increasing burden of kidney failure (KF) in India necessitates provision of cost-effective kidney replacement therapy (KRT). We assessed the comparative cost-effectiveness of initiating KRT with peritoneal dialysis (PD) or haemodialysis (HD) in the Indian context. Methods The cost and clinical effectiveness of starting KRT with either PD or HD were measured in terms of life years (LYs) and quality-adjusted life years (QALYs) using a mathematical Markov model. Complications such as peritonitis, vascular access–related complications and blood-borne infections were considered. Health system costs, out-of-pocket expenditures borne by patients and indirect costs were included. Two scenarios were considered: Scenario 1 (real-world scenario)—as per the current cost and utilization patterns; Scenario 2 (public programme scenario)—use in the public sector as per Pradhan Mantri National Dialysis Programme (PMNDP) guidelines. The lifetime costs and health outcomes among KF patients were assessed. Results The mean QALYs lived per KF person with PD and HD were estimated to be 3.3 and 1.6, respectively. From a societal perspective, a PD-first policy is cost-saving as compared with an HD-first policy in both Scenarios 1 and 2. If only the costs directly attributable to patient care (direct costs) are considered, the PD-first treatment policy is estimated to be cost-effective only if the price of PD consumables can be brought down to INR70/U. Conclusions PD as initial treatment is a cost-saving option for management of KF in India as compared with HD first. The government should negotiate the price of PD consumables under the PMNDP. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. IL-23/IL-17 in a Paradoxical Association with Primary Membranous Nephropathy.
- Author
-
Kaur, Prabhjot, Prabhahar, Arun, Pal, Deeksha, Nada, Ritambhra, Kohli, Harbir Singh, Kumar, Vinod, and Ramachandran, Raja
- Abstract
Primary membranous nephropathy (PMN), an autoimmune disease, is the most common cause of nephrotic syndrome in middle-aged non-diabetic adults. PMN pathophysiology includes Th1/Th2 paradigm. The IL-23/IL-17 pathway is implicated in autoimmune kidney disorders, but no study has examined its relationship with PMN. In several unrelated studies, PMN patients reported to have paradoxical IL-17 levels. This manuscript describes the best possible association of IL-23/IL-17 axis with PMN. Biopsy-proven PMN patients and age, gender-matched healthy controls were enrolled. Serum-PLA2R (Euroimmune, Germany), IL-23 and IL-17 (R&D; USA), was measured using ELISA along with biochemical parameters. Appropriate statistical tools were used for analysis. One hundred eighty-nine PMN patients (mean age 41.70 ± 12.53 years) and 100 controls (mean age 43.92 ± 10.93 years) were identified. One hundred forty were PLA2R-related. PMN patients had median proteinuria, serum albumin, and creatinine of 6.12 (3.875, 9.23) g/day, 2.32 (1.96, 2.9) g/dl, and 0.89 (0.7, 1.1) mg/dl, respectively. IL-17, but not IL-23, was significantly increased in PMN patients compared to controls (IL-17, median: 12.07 pg/ml (9.75, 24.56) vs median: 9.75 pg/ml (8.23, 17.03)
p = 0.0002); (IL23, median: 6.04 pg/ml (4.22, 10.82) vs median: 5.46 pg/ml (3.34, 9.96)p = 0.142). IL-17 and IL-23 correlated significantly (p 0.05) in PMN patients, and similar trend was seen when grouped into PLA2R-related and -unrelated groups. The levels of IL-23 (p = 0.057) and IL-17 (p = 0.004) were high in MN patients that did not respond to the treatment. The current finding may indicate or suggest the involvement of IL-23/IL-17 PMN pathogenesis. A comprehensive investigation is needed to evaluate IL-23/IL-17 axis with renal infiltrating immune cells, and external stimuli. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
18. Anti-Nuclear Antibody-Negative Lupus Nephritis or Post-Infectious Glomerulonephritis: Diagnostic Dilemma in a Young Male.
- Author
-
Bharati, Joyita, Quaiser, Saif, Nada, Ritambhra, Ramachandran, Raja, Kohli, Harbir Singh, and Rathi, Manish
- Subjects
- *
SYSTEMIC lupus erythematosus diagnosis , *STEROID drugs , *AUTOANTIBODIES , *PHYSICAL diagnosis , *PROTEINS , *LUPUS nephritis , *FEVER , *HEMOGLOBINS , *COMPLEMENT (Immunology) , *BIOPSY , *INFLAMMATION , *ORAL drug administration , *DIFFERENTIAL diagnosis , *MYCOPHENOLIC acid , *SERUM albumin , *ELECTRON microscopy , *LEUKOCYTE count , *PLATELET count , *FLUORESCENT antibody technique , *ENZYME-linked immunosorbent assay , *GLOMERULONEPHRITIS , *SYSTEMIC lupus erythematosus , *BLOOD cell count , *POST-infectious disorders , *CREATININE , *THERAPEUTICS - Abstract
Proliferative lupus nephritis (LN) is histologically characterized by endocapillary hypercelMarity and large immune deposits on light microscopy. Immunofluorescence shows almost all immunoglobulins and complement staining. The presence of antinuclear antibodies (ANA) is important for diagnosing systemic lupus erythematosus (SLE). Absence of ANA rules out the possibility of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for SLE. We report a young boy with fever, nephrotic-nephritic syndrome and pancytopenia consistent with hemophagocytic lymphohistiocytosis. Renal biopsy was consistent with LN; however, his initial ANA was negative. In view of pathological features of LN and persistent pancytopenia, high dose steroid therapy was started. Repeat ANA, done during the illness, turned positive. In this report, we describe the relevance of pathological patterns and the uncertainties of ANA positivity in making a diagnosis of SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Gemcitabine-Induced Renal Thrombotic Microangiopathy.
- Author
-
Chaudhary, Ankur, Sethi, Jasmine, Garg, Sahil, Sekar, Aravind, and Kohli, Harbir Singh
- Subjects
- *
PANCREATIC tumors , *PHYSICAL diagnosis , *LIVER tumors , *GEMCITABINE , *DYSPNEA , *TUMOR classification , *THROMBOCYTOPENIA , *BLOOD testing , *URINALYSIS , *COMPUTED tomography , *EDEMA - Published
- 2023
- Full Text
- View/download PDF
20. Deceased Donor Renal Transplantation: A Single Center Experience.
- Author
-
Kapoor, Kunal, Kumar, Sandeep, Sharma, Ashish, Kenwar, Deepesh Benjamin, Singh, Sarbpreet, Shiva, S. P., Kohli, Harbir Singh, and Kaur, Rajinder
- Subjects
- *
HOSPITALS , *GRAFT rejection , *KIDNEY transplantation , *GRAFT survival , *TREATMENT duration , *TREATMENT effectiveness , *HOSPITAL mortality , *KAPLAN-Meier estimator , *DESCRIPTIVE statistics , *HEMODIALYSIS , *ORGAN donation , *EVALUATION - Abstract
Introduction: Deceased donor kidney transplant are still not common across India. This study was done to assess various measures taken at a single center level to increase organ donation rate and to analyse the outcomes of transplants performed from these donors. Methods: All deceased donor renal transplants performed from November 2011 to February 2017 were analysed for patient and death censored graft survival, rate of delayed graft function, rate of rejection and mortality. Kaplan Meir analysis for Survival Curves was used. Results: Organ donation rate at our center improved from one donation every alternate year in 2004 to a peak of 44 donations in 2017. Patient survival was 93.42%, 89.44%, 85.53%, and death censored graft survival was 94.07%, 88.21%, and 82.86% at 1, 2 and 3 years respectively. Mean duration of hemodialysis pre transplantation was 34.6 ± 27.43 months. Conclusions: This study has shown that steps taken at a single center level alone can also significantly improve organ donation rates. Employment of dedicated professionals including transplant surgeons and coordinators, developing a protocol-based approach for referral, and early counseling in triage along with regular audits can help to establish deceased donor program with acceptable outcomes elsewhere in the country. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Primary membranous nephropathy in children and adolescents: a single-centre report from South Asia.
- Author
-
Ramachandran, Raja, Nayak, Saurabh, Kumar, Vinod, Kumar, Ashwani, Agrawal, Neha, Bansal, Ritika, Tiewsoh, Karalanglin, Nada, Ritambhra, Rathi, Manish, and Kohli, Harbir Singh
- Subjects
- *
RITUXIMAB , *IMMUNOSUPPRESSION , *TREATMENT effectiveness , *SERUM albumin , *DESCRIPTIVE statistics , *PROTEINURIA , *GLOMERULONEPHRITIS , *LONGITUDINAL method , *CREATININE - Abstract
Background: Unlike adults, primary membranous nephropathy (PMN) comprises only 1–2% of childhood nephrotic syndrome. The clinical behaviour of PMN in children is not explicit and we report upon clinical presentation and outcome. Methods: This prospective study includes children and adolescents (< 20 years) with biopsy-proven PMN without secondary causes. Anti-PLA2R assessment: before and after completing therapy. Outcome: percentage of patients achieving remission. Results: Study cohort included 48 (M:F ratio 1.1:1) patients and median age 17 (IQR 15–18) years, with 35 (72.9%) PLA2R related. Median interval from symptom onset to presentation was 5 months, where median proteinuria, serum albumin and creatinine were 4.9 g/day, 2.1 g/dL and 0.63 mg/dL, respectively. Forty-seven patients received immunosuppressive therapy, with various agents used as first-line therapy: cyclical CYC/GC (53.1%), CNI/GC (21.3%), rituximab (14.9%), prednisolone alone (4.3%), azathioprine (4.3%) and mycophenolate mofetil (2.1%). Median follow-up was 29 (14, 59) months. At 6 months, 11 (24.4%) and 17 (37.7%) had complete remission (CR) or partial remission (PR), while at last follow-up (median 29 months), 20 (45.4%) and 14 (31.8%) had CR and PR respectively. No significant differences in outcome were observed with different agents. A total of 60% patients treated with rituximab as first line/for relapsing disease, and all cases with resistant disease receiving rituximab had CR or PR at last follow-up. PLA2R antibody presence was associated with clinical outcome. Conclusions: Three-quarters of PMN in children and adolescents is PLA2R related and two-thirds respond to immunosuppressive therapy. Rituximab is a promising agent to manage PMN in children. Anti-PLA2R is associated with clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. Rituximab in treatment of collapsing FSGS—A case series.
- Author
-
Girimaji, Niveditha, Bharati, Joyita, Nada, Ritambhra, Rathi, Manish, Kohli, Harbir Singh, and Ramachandran, Raja
- Subjects
- *
FOCAL segmental glomerulosclerosis , *RITUXIMAB , *SERUM albumin , *IMMUNOSUPPRESSIVE agents , *NEPHROTIC syndrome , *TACROLIMUS - Abstract
Background: Collapsing focal segmental glomerulosclerosis (cFSGS) is an aggressive glomerular disease presenting as a nephrotic syndrome that has lower rates of remission with conventional immunosuppressive therapy and rapidly progresses to end‐stage‐renal‐disease (ESRD). We report eight cases of HIV‐negative cFSGS treated with rituximab. Methods: The current report is a retrospective case series of cFSGS treated with rituximab from January 2011 to March 2020, at varying phases of the disease. Results: Eight out of the 70 cFSGS patients received rituximab. The median age of patients was 30 years (IQR 24.25‐37.5); five patients were males. The median serum creatinine, mean serum albumin and median 24 hours urinary protein at presentation was 0.9 (IQR 0.66‐1.27) mg/dL, 2.95 ± 1.15 g/dL, 4.87 (IQR 1.64‐5.75) g/day, respectively. Two patients were steroid‐resistant, one steroid and tacrolimus dependent, one steroid and cyclosporine dependent, two steroids and tacrolimus resistant, one steroid, tacrolimus, cyclophosphamide, mycophenolate mofetil resistant and one steroid‐resistant and tacrolimus dependent before rituximab therapy. Rituximab was given either as targeted therapy (after an initial dose of 375 mg/m2; patients having CD‐19 levels >5/μL or >1% at 1 month received additional low‐dose [100 mg] of rituximab), or weekly regimen. Five patients received CD‐19 targeted rituximab; three received weekly doses of 375 mg/m2, cumulative doses being 820 ± 228.03 mg, and 1800 ± 721.11 mg, respectively. At the end of median follow‐up of 15 months, five (62.5%) patients were in remission (three partial, two complete remissions), two (25%) were resistant to therapy; one (12.5%) progressed to ESRD. Conclusion: Rituximab is reasonably safe and achieves/maintains remission in 60% of cFSGS cases. SUMMARY AT A GLANCE: This is a retrospective study reporting the effects of Rituximab on 8 patients with the collapsing form of focal segmental glomerulosclerosis. Whilst retrospective in nature, the study suggested that rituximab might be a promising form of treatment for this condition, which is traditionally resistant to immunosuppression therapy, resulting in a remission rate of 60% with a reasonable safety profile. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Outcome of biopsy‐proven lupus nephritis with low glomerular filtration rate at presentation.
- Author
-
Haridasan, Satish, Rathi, Manish, Sharma, Aman, Nada, Ritambhra, Kumar, Sachin, Ramachandran, Raja, and Kohli, Harbir Singh
- Subjects
- *
GLOMERULAR filtration rate , *CHRONIC kidney failure , *KIDNEY failure , *KIDNEY diseases , *LUPUS nephritis , *MYCOPHENOLIC acid - Abstract
Objectives: Currently, there is limited data regarding the outcomes of lupus nephritis (LN) with moderate to severe renal failure at presentation (defined by low glomerular filtration rate; GFR <30 mL/min). Methods: Sixty‐four patients with biopsy‐proven LN and estimated GFR (eGFR) <30 mL/min were prospectively analyzed. Outcome measure of persistently low eGFR, end‐stage renal disease (ESRD) or death at 365 days were grouped as Major Adverse Kidney Events (MAKE365). Results: Diagnosis of lupus was simultaneous with onset of renal disease in 60% of cases. Histologically, 82.3% (n = 51) were class IV, the median serum creatinine was 4 mg/dL (interquartile range [IQR] 3.1‐5.9 mg/dL), median eGFR was 13.75 mL/min (IQR 9.25‐19 mL/min) and 42.2% (n = 27) required dialysis at presentation. Induction regimens included National Institute of Health (68.2%), Eurolupus protocol (10.9%) and mycophenolate mofetil (8%). Over 365 days, 23 (37.5%) subjects died, while 41 (62.5%) survived. The majority of deaths were due to infection and sepsis (14/23). Among the survivors, 70.7% had good renal outcome, 12.1% had persistently low GFR (<30 mL/min), while 17% developed ESRD. In this group, treatment response rate was 84.6% (complete response 25.6%, partial response 59%). Those with a better renal function at presentation had a good treatment response (100% vs. 40%). Altogether, n = 35 (54.6%) were included in the MAKE365 category. Between the renal survival group (n = 29) versus the MAKE365 group (n = 35) there was no difference in clinical or histological parameters. Conclusion: The current treatment protocols had a good response rate in patients with LN even with severe kidney injury at presentation. However, the risk of serious infections and subsequent mortality was high. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. Outcome of biopsy‐proven lupus nephritis with low glomerular filtration rate at presentation.
- Author
-
Haridasan, Satish, Rathi, Manish, Sharma, Aman, Nada, Ritambhra, Kumar, Sachin, Ramachandran, Raja, and Kohli, Harbir Singh
- Abstract
Objectives: Currently, there is limited data regarding the outcomes of lupus nephritis (LN) with moderate to severe renal failure at presentation (defined by low glomerular filtration rate; GFR <30 mL/min). Methods: Sixty‐four patients with biopsy‐proven LN and estimated GFR (eGFR) <30 mL/min were prospectively analyzed. Outcome measure of persistently low eGFR, end‐stage renal disease (ESRD) or death at 365 days were grouped as Major Adverse Kidney Events (MAKE365). Results: Diagnosis of lupus was simultaneous with onset of renal disease in 60% of cases. Histologically, 82.3% (n = 51) were class IV, the median serum creatinine was 4 mg/dL (interquartile range [IQR] 3.1‐5.9 mg/dL), median eGFR was 13.75 mL/min (IQR 9.25‐19 mL/min) and 42.2% (n = 27) required dialysis at presentation. Induction regimens included National Institute of Health (68.2%), Eurolupus protocol (10.9%) and mycophenolate mofetil (8%). Over 365 days, 23 (37.5%) subjects died, while 41 (62.5%) survived. The majority of deaths were due to infection and sepsis (14/23). Among the survivors, 70.7% had good renal outcome, 12.1% had persistently low GFR (<30 mL/min), while 17% developed ESRD. In this group, treatment response rate was 84.6% (complete response 25.6%, partial response 59%). Those with a better renal function at presentation had a good treatment response (100% vs. 40%). Altogether, n = 35 (54.6%) were included in the MAKE365 category. Between the renal survival group (n = 29) versus the MAKE365 group (n = 35) there was no difference in clinical or histological parameters. Conclusion: The current treatment protocols had a good response rate in patients with LN even with severe kidney injury at presentation. However, the risk of serious infections and subsequent mortality was high. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. Rituximab in primary membranous nephropathy: a comparative study of three dosing regimens.
- Author
-
Ramachandran, Raja, Nayak, Saurabh, Kumar, Vinod, Sethi, Jasmine, Minz, Ranjana, Kumar, Vivek, Rathi, Manish, and Kohli, Harbir Singh
- Subjects
- *
RITUXIMAB , *KIDNEY diseases , *VENTRICULAR septal defects - Published
- 2021
- Full Text
- View/download PDF
26. Reversal of endothelial dysfunction post-immunosuppressive therapy in adult-onset podocytopathy and primary membranous nephropathy.
- Author
-
Inamdar, Neeraj, Tomer, Shallu, Kalmath, Sunil, Bansal, Akash, Yadav, Ashok Kumar, Sharma, Vishal, Bahuguna, Pankaj, Gorsi, Ujjwal, Arora, Sunil, Lal, Anupam, Kumar, Vivek, Rathi, Manish, Kohli, Harbir Singh, Gupta, Krishan Lal, and Ramachandran, Raja
- Subjects
- *
T cells , *SERUM albumin , *NEPHROTIC syndrome , *CELL populations , *ENDOTHELIUM diseases , *IMMUNOSUPPRESSIVE agents - Abstract
The effect of nephrotic syndrome (NS) and its treatment on endothelial dysfunction is not evident. This study assessed endothelial dysfunction in adult-onset NS and its impact of immunosuppressive therapy. Newly diagnosed patients with adult-onset NS (podocytopathy and primary membranous nephropathy (PMN)) and normal renal function were enrolled. Flow mediated vasodilatation (FMD) assessed endothelial function and CD4+CD28null T cells, E-selectin and pulse wave velocities (PWV) were measured at baseline and after treatment to characterize this further. Monitoring included monthly proteinuria, serum albumin, creatinine and lipid profile at baseline and post-treatment. The healthy control (HC) included 25 voluntary kidney donors who were assessed for markers of endothelial dysfunction. Fifty participants with new-onset NS were studied. Amongst the NS group, 26 (52%) patients had PMN, while the remaining 24 (48%) had podocytopathy. Twenty-one (88%) patients in the podocytopathy and 18 (69%) patients in the PMN cohort were in either complete or partial remission at the end of 8 months. FMD at baseline in NS patients was significantly lower as compared to HC (p = 0.002) while PWV (p = 0.007), E-selectin (p < 0.001) and CD4+CD28null T cells (p = 0.003) were significantly higher as compared with HC. Following treatment with immunosuppressive medication, FMD increased from 3 to 8% (p < 0.001). PWV also improved from a baseline of 7.70 to 6.65 m/s (p = 0.001). At the end of 8 months, E-selectin decreased significantly from 127 to 82 ng/ml (p = 0.002) while the CD4+CD28null T cell population reduced from 5.20 to 3.70% (p = 0.032) of total CD4+ cells. In the PMN cohort, despite significant reduction, E-selectin and CD4+CD28null T cells at follow-up remained higher than in healthy controls. Immunosuppressive treatment contributes substantially to the improvement of endothelial dysfunction present at baseline in NS patients. Persistent subtle endothelial dysfunction remains in the sub-group of patients with PMN. Image 1 • As compared to healthy controls, patients with nephrotic syndrome have endothelial dysfunction at presentation. • Immunosuppressive drugs contribute substantially to improvement in endothelial dysfunction. • Despite treatment, subtle endothelial dysfunction persists in primary membranous nephropathy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. Reversal of endothelial dysfunction post-immunosuppressive therapy in adult-onset podocytopathy and primary membranous nephropathy.
- Author
-
Inamdar, Neeraj, Tomer, Shallu, Kalmath, Sunil, Bansal, Akash, Yadav, Ashok Kumar, Sharma, Vishal, Bahuguna, Pankaj, Gorsi, Ujjwal, Arora, Sunil, Lal, Anupam, Kumar, Vivek, Rathi, Manish, Kohli, Harbir Singh, Gupta, Krishan Lal, and Ramachandran, Raja
- Subjects
- *
T cells , *SERUM albumin , *NEPHROTIC syndrome , *CELL populations , *ENDOTHELIUM diseases , *IMMUNOSUPPRESSIVE agents - Abstract
The effect of nephrotic syndrome (NS) and its treatment on endothelial dysfunction is not evident. This study assessed endothelial dysfunction in adult-onset NS and its impact of immunosuppressive therapy. Newly diagnosed patients with adult-onset NS (podocytopathy and primary membranous nephropathy (PMN)) and normal renal function were enrolled. Flow mediated vasodilatation (FMD) assessed endothelial function and CD4+CD28null T cells, E-selectin and pulse wave velocities (PWV) were measured at baseline and after treatment to characterize this further. Monitoring included monthly proteinuria, serum albumin, creatinine and lipid profile at baseline and post-treatment. The healthy control (HC) included 25 voluntary kidney donors who were assessed for markers of endothelial dysfunction. Fifty participants with new-onset NS were studied. Amongst the NS group, 26 (52%) patients had PMN, while the remaining 24 (48%) had podocytopathy. Twenty-one (88%) patients in the podocytopathy and 18 (69%) patients in the PMN cohort were in either complete or partial remission at the end of 8 months. FMD at baseline in NS patients was significantly lower as compared to HC (p = 0.002) while PWV (p = 0.007), E-selectin (p < 0.001) and CD4+CD28null T cells (p = 0.003) were significantly higher as compared with HC. Following treatment with immunosuppressive medication, FMD increased from 3 to 8% (p < 0.001). PWV also improved from a baseline of 7.70 to 6.65 m/s (p = 0.001). At the end of 8 months, E-selectin decreased significantly from 127 to 82 ng/ml (p = 0.002) while the CD4+CD28null T cell population reduced from 5.20 to 3.70% (p = 0.032) of total CD4+ cells. In the PMN cohort, despite significant reduction, E-selectin and CD4+CD28null T cells at follow-up remained higher than in healthy controls. Immunosuppressive treatment contributes substantially to the improvement of endothelial dysfunction present at baseline in NS patients. Persistent subtle endothelial dysfunction remains in the sub-group of patients with PMN. Image 1 • As compared to healthy controls, patients with nephrotic syndrome have endothelial dysfunction at presentation. • Immunosuppressive drugs contribute substantially to improvement in endothelial dysfunction. • Despite treatment, subtle endothelial dysfunction persists in primary membranous nephropathy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy.
- Author
-
Bharati, Joyita, Tiewsoh, Karalanglin, Kumar, Ashwani, Nada, Ritambhra, Rathi, Manish, Gupta, Krishan Lal, Kohli, Harbir Singh, Jha, Vivekananda, and Ramachandran, Raja
- Subjects
- *
MYCOPHENOLIC acid , *CHRONIC kidney failure , *NEPHROTIC syndrome , *MEDICAL records , *IMMUNOSUPPRESSIVE agents - Abstract
Background C3 glomerulopathy (C3G) is a heterogeneous disease caused by alternative complement pathway abnormalities without any standardized treatment. An immunosuppressive agent, mycophenolate mofetil (MMF), has been recently shown to be useful in treating C3G, mainly in studies from the west. We report the clinical outcome of 17 Indian C3G patients treated with MMF with or without steroids. Methods The clinical and histology details of the C3G patients treated with MMF for at least 6 months with a follow-up of at least 12 months were retrieved from the medical records of our center. Results The median serum creatinine and proteinuria at presentation were 0.8 mg/dL and 3.7 g/day, respectively, with the majority (88.2%) presenting as nephrotic syndrome. The mean dose of MMF was 1.65 (±0.56) g/day, and the median duration of MMF therapy was 18 months. Two-thirds (64%) of the patients responded to the treatment, with complete remission in 4 (23%) and partial remission in 7 (41%) (median time: 9 months). Three patients progressed to end-stage renal disease (ESRD) on follow-up. Of the three patients, one (33%) had an initial response in proteinuria to MMF but did not respond after a relapse and subsequently progressed to ESRD and two (67%) other patients were nonresponsive to MMF from the start of the therapy. Conclusion Despite a small sample size and lack of a control arm, this study describes the effectiveness of MMF in treating C3G patients from Asia and forms a basis for future randomized trials. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
29. Visceral infarction in systemic lupus erythematosus mimicking medium-vessel vasculitis.
- Author
-
Sharma, Aakanksha, Sethi, Jasmine, Gupta, Raghav, Sanyasi, Sandeep Kumar, and Kohli, Harbir Singh
- Subjects
- *
SYSTEMIC lupus erythematosus diagnosis , *ANTIBIOTICS , *METHYLPREDNISOLONE , *FEVER , *BIOPSY , *INFARCTION , *BLOOD chemical analysis , *TRANSESOPHAGEAL echocardiography , *PATIENTS , *SPLEEN diseases , *KIDNEY diseases , *HOSPITAL admission & discharge , *INFECTIVE endocarditis , *SYSTEMIC lupus erythematosus , *ABDOMINAL pain , *COMPUTED tomography , *VASCULITIS , *ABDOMINAL radiography , *FIBRIN fibrinogen degradation products , *DISEASE complications - Abstract
The authors describes a rare case of splenic and renal infarction in a patient as a presenting manifestation of systemic lupus erythematosus (SLE), probably due to lupus vasculitis. Topics discussed include findings on the laboratory examinations of the patient, prevalence rate of vasculitis in SLE, and basis of the diagnosis of lupus vasculitis.
- Published
- 2022
- Full Text
- View/download PDF
30. Membranous nephropathy with light chain restricted deposits.
- Author
-
Ramachandran, Raja, Inamdar, Neeraj, Bharati, Joyita, Yadav, Ashok K., Rathi, Manish, Kohli, Harbir Singh, Gupta, Krishan L., Kumar, Ashwani, Nada, Ritambhra, Prakash, Gaurav, and Jha, Vivekanand
- Subjects
- *
KIDNEY diseases , *IMMUNOFLUORESCENCE , *CREATININE , *MONOCLONAL antibodies , *PHOSPHOLIPASE A2 , *LYMPHOPROLIFERATIVE disorders , *CYCLOPHOSPHAMIDE , *STEROIDS - Abstract
Abstract: The literature on membranous nephropathy (MN) with monoclonal deposits on immunofluorescence (IF) and their outcome is very scarce. We report our experience of managing five patients with this clinical entity. The mean age of the patients was 33.2 ± 6.55 years. The mean proteinuria, serum albumin and serum creatinine was 5.73 ± 2.17 g/day, 2.86 ± 0.51 g/dL and 1.34 ± 1.19 mg/dL, respectively. None of the patients had a lymphoproliferative disorder. Only one patient had an elevated free light chain ratio. Four (80%) patients were M‐type phospholipase A2 receptor (PLA2R) negative (tissue and serum), and one (20%) was PLA2R related. Three (60%) cases had monoclonal IgG3/k, one IgG3/λ, whereas one patient with PLA2R positivity had an IgG3/IgG4k subtype. Two (67%) patients treated with cyclical cyclophosphamide and steroids (cCYC/GC) achieved complete remission and one patient (33%) with elevated baseline creatinine had a reduction in serum creatinine with persistent proteinuria at the end of the 12th month of follow‐up. One patient with PLA2R positive MN was treated with Rituximab and is in complete remission. The patient with an elevated free light chain at baseline was treated with Bortezomib/Thalidomide/Dexamethasone, had complete remission at 12 months, however, had a progressive rise in creatinine over the next 40 months of follow‐up. The current series, though limited by numbers, documents the efficacy of conventional therapies in non‐malignant associated MN with monoclonal deposits on IF. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
31. Comparison of Two Steroid Regimens in Induction Therapy of Proliferative Lupus Nephritis: A Randomized Controlled Trial.
- Author
-
Bharati, Joyita, Rathi, Manish, Ramachandran, Raja, Sharma, Aman, Kumar, Vivek, Kohli, Harbir Singh, and Gupta, Krishan Lal
- Subjects
- *
MYCOPHENOLIC acid , *COMBINATION drug therapy , *LUPUS nephritis , *TREATMENT effectiveness , *THERAPEUTICS ,THERAPEUTIC use of glucocorticoids - Published
- 2019
- Full Text
- View/download PDF
32. Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
- Author
-
Taneja, Sunil, Duseja, Ajay, De, Arka, Mehta, Manu, Ramachandran, Raja, Kumar, Vivek, Kohli, Harbir Singh, Gupta, Krishan Lal, Dhiman, Radha Krishan, and Chawla, Yogesh
- Subjects
- *
CHRONIC hepatitis C , *CHRONIC kidney failure , *MEDICATION safety , *DRUG efficacy , *PATIENTS , *THERAPEUTICS ,SOFOSBUVIR - Abstract
Background and Aims: There is sparse data on the use of Sofosbuvir based directly acting antiviral (DAA) drug regimens in chronic hepatitis C (CHC) patients with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m2. We evaluated the safety and efficacy of low-dose Sofosbuvir plus full-dose Daclatasvir in CHC patients with CKD.Methods: Sixty-five CHC patients with CKD with eGFR less than 30 mL/min/1.73 m2 [54 (83%) patients with ESRD on hemodialysis] were included. All patients irrespective of genotype were treated with half-dose Sofosbuvir [200 mg (half tablet of 400 mg)] plus full-dose Daclatasvir (60 mg) given daily for either 12 or 24 weeks given in patients with genotype 3 cirrhosis. The efficacy was assessed by the sustained virological response (SVR12) with negative HCV RNA 12 weeks after the end of treatment (ETR).Results: The median HCV RNA level in 65 patients (Males 40, mean age 42.9 ± 13 years) was 1.65 × 106 (1.2 × 103-1.73 × 108) IU/mL with 42 (64.6%) patients having HCV genotype 1, followed by genotype 3 and 2 in 22 (34%) and 1 (1.4%) patients, respectively. Twenty-one (32%) patients had evidence of cirrhosis, and ten (15.4%) patients were treatment experienced. Sixty-four (98.5%) patients achieved ETR, and 65 (100%) patients attained SVR12. All patients tolerated the DAAs well with none of the patients reporting any serious adverse events. Minor side effects noted were nausea seen in five (7.7%) patients, insomnia and headache in four (6.2%) patients each, and pruritus in one (1.5%) patient.Conclusion: Low-dose Sofosbuvir and full-dose Daclatasvir are safe and effective in treating CHC in patients with CKD with eGFR less than 30 mL/min/1.73 m2. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
33. PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians.
- Author
-
Ramachandran, Raja, Kumar, Vinod, Kumar, Ashwani, Yadav, Ashok Kumar, Nada, Ritambhra, Kumar, Harsha, Kumar, Vivek, Rathi, Manish, Kohli, Harbir Singh, Gupta, Krishan Lal, Sakhuja, Vinay, and Jha, Vivekanand
- Subjects
- *
KIDNEY diseases , *PHOSPHOLIPASE A2 , *ALLELES , *SOUTH Asians , *KIDNEY glomerulus , *HLA histocompatibility antigens , *DISEASES , *GENETICS - Abstract
Background. Antibodies to M-type phospholipase A2 receptor (PLA2R) correlate with clinical activity of primary membranous nephropathy (PMN). Risk alleles in PLA2R1 and HLA-DQA1 genes are associated with PMN. Whether these alleles are associated with the development of anti-PLA2R is unknown. In this prospective study we evaluated anti-PLA2R, enhanced glomerular staining for PLA2R and variations in PLA2R1 and HLA-DQA1 genes in Indian patients with PMN and examined their association with response to treatment. Methods. A total of 114 adult PMN patients were studied. Anti-PLA2R was estimated before treatment and after 6 and 12 months of therapy. Enhanced glomerular staining for PLA2R was assessed on fresh frozen tissue. Genotype analysis was done on recruited patients and 95 healthy controls by Taq- Man assays for six single-nucleotide polymorphisms (SNPs; rs4664308, rs3749119, rs3749117, rs4664308, rs3828323 and rs2187668). Patients were followed up monthly for a period of 12 months. Results. Of 114 patients, 66.7% showed elevated serum anti- PLA2R by ELISA and 64.9% by indirect immunofluorescence. About 75% had enhanced glomerular staining for PLA2R. A total of 82% of patients had PLA2R-related disease. Reduction in serum anti-PLA2R titer had a significant association with remission of nephrotic syndrome (P = 0.0003) at 6 and 12 months. More than 85% of patients showing >90% reduction in the anti- PLA2R titer achieved remission of the nephrotic state, whereas of those showing <50% reduction in titers, 87.5% had persistent nephrotic state. The SNPs rs3749119, rs3749117, rs4664308 in PLA2R1 and rs2187668 in HLA-DQA1 were significantly associated with PMN. The SNP rs2187668 was associated with anti-PLA2R positivity. Patients with a high-risk genotype had higher anti-PLA2R levels. Conclusion. To conclude, anti-PLA2R and enhanced glomerular PLA2R staining are found in more than two-thirds of Indian PMN cases. A reduction in the anti-PLA2R titer correlated with response to therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
34. IgG4-related tubulointerstitial nephritis: A prospective analysis.
- Author
-
Nada, Ritambhra, Ramachandran, Raja, Kumar, Ashwani, Rathi, Manish, Rawat, Amit, Joshi, Kusum, Kohli, Harbir Singh, and Gupta, Krishan Lal
- Subjects
- *
IMMUNOGLOBULIN G , *INTERSTITIAL nephritis , *HISTOLOGY , *KIDNEY diseases , *BIOPSY - Abstract
Aims Immunoglobulin-G4 (IgG4)-related tubulo-interstitial nephritis (IgG4 TIN) could be the first presentation of IgG4-related systemic disease. Most of the data is from the West or Japan and retrospective, with good patient outcome. Methods This study was carried out from April 2011 to July 2013. We report a prospective follow-up of 11 patients who presented with renal dysfunction and had histological diagnosis of IgG4 TIN followed for a minimum period of 1 year or until end-stage renal disease. Results IgG4 TIN constituted 0.28% of total renal biopsies and 6.5% of all tubulointerstitial nephritis. Patient ages ranged between 21 and 71 years with a male predominance. All the patients had renal dysfunction at presentation with a mean serum creatinine of 5.12 mg/dL. Proteinuria was subnephrotic except when there was coexisting membranous glomerulonephritis (36.4%). The mean 24-h urine protien excretion was 1.8 g. Serum IgG4 levels were elevated in 10 (90.9%) patients. Ten (90.9%) patients had renomegaly and one (9.1%) had focal renal mass. Extra-renal manifestations were present in seven (63.6%). Renal histology showed pattern A in five (45.5%), pattern B in four (36.3%) and pattern C in two (18.1%) patients. All but one patient (90.9%) received immunosuppressive therapy. Four (36.3%) achieved complete remission and three (27.2%) progressed to end stage renal disease. Two patients died due to infections while on steroid therapy. One patient with a mass had end stage renal disease for 12 months and did not improve with steroid therapy, and one (pattern C) had progressive chronic kidney disease on follow-up. Conclusion IgG4 TIN in an Indian cohort most often presents with rapidly progressive renal failure and less often has extra-renal organ involvement. On follow-up, patients can experience a more aggressive course with progression to end stage renal disease. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
35. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
- Author
-
Ramachandran, Raja, Hn, Harsha Kumar, Kumar, Vinod, Nada, Ritambhra, Yadav, Ashok Kumar, Goyal, Ajay, Kumar, Vivek, Rathi, Manish, Jha, Vivekanand, Gupta, Krishan Lal, Sakhuja, Vinay, and Kohli, Harbir Singh
- Subjects
- *
KIDNEY disease treatments , *TACROLIMUS , *CORTICOSTEROIDS , *RANDOMIZED controlled trials , *PHOSPHOLIPASES - Abstract
Aim There have been very few studies comparing cyclophosphamide ( CTX) and calcineurin inhibitor based regimens in the management of non-immunosuppressive symptomatic therapy ( NIST) resistant idiopathic membranous nephropathy ( IMN). The present study was aimed at comparing the efficacy and safety of tacrolimus ( TAC)/steroids with cyclical CTX/steroids ( Modified Ponticelli regimen ( MPR)) in patients with IMN. Methods Idiopathic membranous nephropathy patients ( n = 70) with persistent nephrotic syndrome after at least 6 months of antiproteinuric therapy or with complications of nephrotic syndrome were equally randomized to receive TAC with oral prednisolone ( TAC*) or MPR. Antibodies against m-type phospholipase A2 receptor ( PLA2R Ab) were tested for at baseline and, at 6 and 12 months after the start of therapy. The primary end point was achievement of remission and secondary objectives were adverse effects and estimated glomerular filtration rate in both the study groups. Results Intention-to-treat analysis showed that remissions at the end of 6 (74% with TAC* vs. 60% with MPR; P = 0.30) and 12 months (71% with TAC* vs. 77% with MPR; P = 0.78) were comparable. PLA2R Ab titres at 6/12 months correlated with urine protein (r 0.54/0.58) and serum albumin (r −0.49/−0.53) at the end of therapy. Patients on CTX had a significantly higher risk of amenorrhea and while those on TAC had a greater risk of reversible nephrotoxicity. Conclusion In NIST refractory IMN, both TAC* and MPR are comparable, but with different adverse effect profile. PLA2R Ab has a very good association with proteinuria, and should be regularly monitored on clinical follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
36. Pauci-immune glomerulonephritis: does negativity of anti-neutrophilic cytoplasmic antibodies matters?
- Author
-
Sharma, Aman, Nada, Ritambra, Naidu, Godasi S. R. S. N. K., Minz, Ranjana W., Kohli, Harbir Singh, Sakhuja, Vinay, Gupta, Krishan Lal, and Rathi, Manish
- Subjects
- *
GLOMERULONEPHRITIS , *ANTINEUTROPHIL cytoplasmic antibodies , *IMMUNOPATHOLOGY , *IMMUNOFLUORESCENCE , *DISEASE complications , *PROGNOSIS - Abstract
Aim A significant proportion of pauci-immune glomerulonephritis ( PIGN) patients are reported to have absence of anti-neutrophilic cytoplasmic antibodies ( ANCA). However, studies are controversial regarding their significance and there is limited data after the new prognostic classification of PIGN. Methods Renal biopsy-proven cases of PIGN were included and their clinical details, ANCA status by immunofluorescence ( IIF) and enzyme-linked immunosorbent assay ( ELISA), Birmingham Vasculitis Activity Score ( BVAS) and treatment outcomes at 6 months were noted. The renal biopsies were classified according to the proposed histopathological classification. Scoring was done from 0-3 for interstitial edema, interstitial fibrosis and tubular atrophy ( IFTA), interstitial inflammation and arteriosclerosis. The percentage of glomeruli with sclerosis, cellular and fibrous crescents, and percentage of subjects with glomerulitis, tuft necrosis, interstitial granuloma and vasculitis were noted. Results Out of the 84 subjects included in the study, 33 (39.3%) were negative for ANCA by both IIF and ELISA. These subjects had significantly higher renal involvement, less extra-renal manifestations and lower BVAS. On histology, they had significantly higher proportion of crescentic class (66.7% vs. 41.2%, P = 0.039), higher number of cellular crescents (66.12% vs. 53.3%, P = 0.00008), higher IFTA (1.53 vs. 1.02, P = 0.009) and less interstitial edema (1.44 vs. 1.96, P = 0.003). The treatment outcomes were worse in ANCA-negative PIGN subjects, with significantly less improvement (37.2% vs. 62.8%, P = 0.02), more deterioration (40.7% vs. 14%, P = 0.006), and reduced probability of becoming dialysis free (31.6% vs. 69.6% P = 0.009). Conclusions A negative ANCA in PIGN is associated with crescentic class, more IFTA and poor treatment outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
37. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy.
- Author
-
Kumar, Vinod, Ramachandran, Raja, Kumar, Ashwani, Nada, Ritambhra, Suri, Deepti, Gupta, Anju, Kohli, Harbir Singh, Gupta, Krishan Lal, and Jha, Vivekanand
- Subjects
- *
PHOSPHOLIPASE A2 , *KIDNEY diseases , *RECEPTOR antibodies , *NEPHROTIC syndrome in children , *KIDNEY glomerulus - Abstract
Idiopathic membranous nephropathy ( IMN), the commonest cause of adult nephrotic syndrome ( NS), accounts for only a minority of paediatric NS. Antibodies to m-type phospholipase A2 receptor ( PLA2R) are seen in two-thirds of adult IMN cases. PLA2R staining in glomerular deposits is observed in 74% and 45% of adult and paediatric IMN cases, respectively. However, there are no reports of anti- PLA2R in paediatric IMN. We evaluated anti- PLA2R levels and PLA2R in gloemrular deposits in paediatric IMN seen at our center. Five cases were enrolled, all the cases stained for PLA2R in glomeruli and three (60%) had antibodies to PLA2R antigen. There was a parellel reduction in proteinuria and anti- PLA2R titer. The present report suggests that PLA2R has a contributory role in the pathogenesis of paediatric IMN. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
38. Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience.
- Author
-
Ramachandran, Raja, Kumar, Vivek, Rathi, Manish, Nada, Ritambhra, Jha, Vivekanand, Gupta, Krishan Lal, Sakhuja, Vinay, and Kohli, Harbir Singh
- Subjects
- *
TACROLIMUS , *STEROIDS , *NEPHROTIC syndrome , *GLOMERULOSCLEROSIS , *NEPHROTOXICOLOGY , *HYPERGLYCEMIA , *DIABETES , *THERAPEUTICS - Abstract
Introduction Management of adults with steroid-resistant (SR) nephrotic syndrome due to focal segmental glomerulosclerosis (FSGS) is a challenging task. Is tacrolimus (TAC) effective in this situation without serious adverse effects? This prospective study was done to answer this question. Materials and methods In patients with SR nephrotic syndrome due to FSGS, oral TAC (0.1 mg/kg/day) was started targeting a trough level of 5–10 ng/mL along with oral prednisolone (0.15 mg/kg/day) for 48 weeks. In patients with complete remission (CR), TAC dose was reduced to a target of 3–6 ng/mL whereas in partial responders, TAC trough levels were kept at 5–10 ng/mL. TAC was discontinued in those with no remission at 24 weeks and was deemed TAC resistant. Outcome, namely CR and partial remission (PR), was assessed at the end of 24 and 48 weeks. All patients were prospectively followed for 60 weeks. Relapses after CR or PR were recorded; adverse effects, namely nephrotoxicity (>25% rise in creatinine), cosmetic effects, infections and hyperglycemia, were recorded every month. Results A total of 44 SR-FSGS [not otherwise specified 33 (75%), tip lesion 03 (6.8%) and cellular variant 8 (18.1%)] were analyzed. Mean age was 25.16 ± 8.26 (18–51) years. Of 44 patients, CR and PR were achieved in 17 (38.6%) and 06 (13.6%) patients, respectively. TAC resistance was seen in 21 (47.7%) patients. Time taken to achieve remission was 15.2 ± 6 weeks. Five (21.7%) patients with CR had relapse on tapering the dose and seven (30.4%) after stopping TAC. Reversible nephrotoxicity was seen in seven (15.9%) and irreversible in four patients (9%). TAC-related diarrhea was the problem in 10 (22.7%), and infections were seen in 19 patients (43.1%). Impaired fasting glucose and diabetes mellitus were seen in 10 patients (22.7%). Conclusion TAC is an effective agent in the management of SR-FSGS. However, strict renal function and blood sugar monitoring is required due to its potential nephrotoxicity and diabetogenic potential. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
39. A rare case of cytomegalovirus, scedosporium apiospermum and mycobacterium tuberculosis in a renal transplant recipient.
- Author
-
Rathi, Manish, Gundlapalli, Srikant, Ramachandran, Raja, Mohindra, Sandeep, Kaur, Harsimran, Kumar, Vivek, Kohli, Harbir Singh, Gupta, Krishan Lal, and Sakhuja, Vinay
- Subjects
- *
INFECTION , *CYTOMEGALOVIRUSES , *MYCOBACTERIUM tuberculosis , *TUBERCULIN , *POLYMERASE chain reaction - Abstract
Background Renal transplant recipients are at high risk of developing multiple infections, often concomitantly because of their immunocompromised status. Post renal transplant infections are often elusive and require extensive evaluation for proper diagnosis and treatment. A high index of suspicion is required and an attempt should be made to confirm the microbiological diagnosis from each site involved to rule out multiple infections. Case presentation We report a 50-year-old female, a renal allograft recipient who presented with left hemiplegia, esophageal ulcers and fever 3 months after her transplant. Esophageal biopsy revealed Cytomegalovirus (CMV) inclusions and the whole blood quantitative CMV polymerase chain reaction (PCR) was positive. Neuroimaging showed a brain abscess, stereotactic biopsy from which revealed Scedosporium apiospermum on fungal culture. Her tacrolimus and mycophenolate were stopped and she was managed with intravenous ganciclovir and voriconazole. With these measures, she showed marked improvement in her general and neurological condition. Two months later, she developed recurrence of fever with dry cough. Radiological investigation revealed a cavitating lung lesion, a needle aspiration from which demonstrated acid-fast bacilli. She was started on antituberculous treatment. With these measures, she recovered completely and maintained good graft function despite being on only prednisolone 10 mg once a day. Conclusion Although CMV disease is not uncommon in the first three months post transplant, Scedosporium is a rare cause of brain abscess. On the other hand, tuberculosis is common in transplant recipients, especially in developing countries, like India. However, this is the first case report of occurrence of these three infections in the same patient, demonstrating the importance of a good microbiological work-up from each site involved in immunosuppressed subjects. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
40. Recurrence of ANCA-negative renal-limited pauci-immune glomerulonephritis in the renal allograft.
- Author
-
Rajkumar, Venkatesh, Gowda, Kiran Krishne, Jha, Vivekanand, Kohli, Harbir Singh, Kumar, Vivek, and Ramachandran, Raja
- Subjects
- *
GLOMERULONEPHRITIS , *METHYLPREDNISOLONE , *CYCLOPHOSPHAMIDE , *PLASMAPHERESIS , *HOMOGRAFTS - Abstract
The article presents a case study of 16-year-old adolescent male with anti-neutrophil cytoplasmic antibody (ANCA) negative renal-limited form of pauci-immune crescentic glomerulonephritis (PICGN) who developed end-stage renal disease (ESRD) despite treatment. He treated with methylprednisolone, cyclophosphamide and plasmapheresis and result showed a rare recurrence of renal-limited PICGN in the allograft.
- Published
- 2013
- Full Text
- View/download PDF
41. Association of an Osteopontin gene promoter polymorphism with susceptibility to diabetic nephropathy in Asian Indians
- Author
-
Cheema, Balneek Singh, Iyengar, Sreenivasa, Ahluwalia, Tarunveer Singh, Kohli, Harbir Singh, Sharma, Rajni, Shah, Viral N., Bhansali, Anil, Sakhuja, V., and Khullar, Madhu
- Subjects
- *
OSTEOPONTIN , *GENETIC polymorphisms , *DIABETIC nephropathies , *DISEASE susceptibility , *DIABETES complications , *INDIANS (Asians) - Abstract
Abstract: Genetic predisposition has been proposed to be a major determinant in the development of renal complications of diabetes. Osteopontin (OPN) has been suggested to be associated with renal diseases characterized by tubulointerstitial fibrosis and proteinuria. However, information on association of genetic polymorphisms in OPN with diabetic nephropathy is lacking. Thus, the present study was designed with the aim to examine the association of an OPN gene promoter polymorphism with diabetic nephropathy in Asian Indians. OPN C-443T (rs11730582) polymorphism was determined in 1115 type 2 diabetic patients belonging to two independently ascertained cohorts using Real time PCR based Taqman assay. We observed a nearly threefold elevated risk of diabetic nephropathy among carriers of T allele and TT genotype of OPN C‐443T polymorphism. Further, this allele was found to be significantly associated with proteinuria and lower eGFR, a hallmark of diabetic nephropathy, in both our cohorts. This is the first study which suggests that OPN C-443T polymorphism may be a significant risk factor for diabetic nephropathy in type 2 diabetic patients. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
42. Common Variants of Inflammatory Cytokine Genes Are Associated with Risk of Nephropathy in Type 2 Diabetesamong Asian Indians.
- Author
-
Ahluwalia, Tarunveer Singh, Khullar, Madhu, Ahuja, Monica, Kohli, Harbir Singh, Bhansali, Anil, Mohan, Viswanathan, Venkatesan, Radha, Rai, Taranjit Singh, Sud, Kamal, and Singal, Pawan K.
- Subjects
- *
GENETICS of diabetes , *CELLULAR immunity , *KIDNEY diseases , *GENETIC polymorphisms , *CARBOHYDRATE intolerance , *INDIANS (Asians) - Abstract
Background: Inflammatory cytokine genes have been proposed as good candidate genes for conferring susceptibility to diabetic nephropathy. In the present study, we examined the combined effect of multiple alleles of pro inflammatory cytokine genes for determining the risk of nephropathy in type 2 diabetic patients. Methodology/Principal Findings: Eight single nucleotide polymorphisms (SNPs) of pro-inflammatory cytokine genes (CCL2, TGFB1, IL8, CCR5, and MMP9) were genotyped in two independently ascertained type 2 diabetic cohorts with (DN) and without nephropathy (DM); consisting of patients from North India (n = 495) and South India (n = 188). Genotyping was carried out using PCR, allele specific oligonucleotide-PCR (ASO-PCR), PCR-RFLP and TaqMan allelic discrimination assays and the gene-gene interaction among genetic variants were determined by multi dimensional reduction (MDR) software. Serum high sensitive CRP (hs-CRP) levels were measured by ELISA. The hs-CRP levels were significantly higher in DN as compared to the DM group (p<0.05). The CCL2, IL8, CCR5 and MMP9 polymorphisms were found to be associated with the risk of diabetic nephropathy. Frequency of CCL2 II, IL8 -251AA, CCR5 59029AA and MMP9 279Gln/Gln genotypes were significantly higher in DN than in DM group (p<0.05) and associated with an increased risk of nephropathy in both North and South Indian cohorts. CCR5 DD and IL8 -251AA genotypes were more prevalent in North Indian DN group only. The co-occurrence of risk associated genotypes (II, -2518GG (CCL2), DD (CCR5) and 279Gln/Gln (MMP9) conferred a tenfold increased risk of nephropathy among type 2 diabetics (p<0.0002). Conclusion: The present study highlights that common variants of inflammatory cytokine genes exert a modest effect on risk of DN and a combination of risk alleles confer a substantial increased risk of nephropathy in type 2 diabetes among Asian Indians. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
43. ACE Variants Interact with the RAS Pathway to Confer Risk and Protection against Type 2 Diabetic Nephropathy.
- Author
-
Ahluwalia, Tarunveer Singh, Ahuja, Monica, Rai, Taranjit Singh, Kohli, Harbir Singh, Bhansali, Anil, Sud, Kamal, and Khullar, Madhu
- Subjects
- *
RENIN-angiotensin system , *ANGIOTENSIN converting enzyme , *TYPE 2 diabetes , *DIABETIC nephropathies , *GENETIC polymorphisms , *DISEASE susceptibility - Abstract
Genetic predisposition has been proposed to be a major determinant in the development of renal complications of diabetes. Among candidate genes examined for susceptibility to diabetic nephropathy, angiotensin-converting enzyme ( ACE) gene has been found to be associated with pathogenesis and progression of diabetic nephropathy. However, the role of other renin-angiotensin system (RAS) polymorphisms and their possible interactions with different ACE I/D genotypes are less clearly defined. Recent studies also show that ACE haplotypes may be better predictors to disease susceptibility. Thus, in the present study, we evaluated the association of ACE haplotypes and the interactions of ACE, angiotensinogen ( AGT), and angiotensin II receptor type I ( AGTR1) gene polymorphisms with DNP in Asian Indians. We genotyped seven variants of the RAS pathway genes ( ACE, AGT, and AGTR1) in type 2 diabetic cohorts without nephropathy (DM) and with nephropathy (DNP), using allele-specific oligonucleotide–PCR, and PCR–restriction fragment length polymorphism assays. We studied the interaction of these variants with each other and ACE I/D polymorphism. Frequency of ACE D allele and DD genotype ( ACE I/D) was significantly higher in DNP ( p < 0.005) and was associated with increased risk of nephropathy. The frequency of T allele, MT/TT genotypes ( AGT: M235T), and C allele 1166CC genotype ( AGTR1: A1166C) was higher and associated with increased risk of DNP (235T, p < 0.0001; 235TT/MT, p < 0.01; 1166C, p < 0.007; 1166CC, p < 0.0001). The ACE locus revealed a near doubling in the prevalence of T-D-G risk haplotype (odds ratio, 1.76) in DNP (0.13) compared to DM (0.08; p < 0.02). ACE haplotypes carrying the I allele were associated with a lower risk of DNP (C-I-A, p < 0.04; C-I-G, p < 0.008). ACE ID/DD genotypes in combination with ACE rs4311, rs4343, and AGT rs699 mutant genotypes increased the risk of DNP development fourfold ( p < 0.01). This study provides the first evidence for a disease haplotype for DNP at the ACE locus in Asian Indians. The study further indicates that ACE D allele individually and in interaction with other RAS single-nucleotide polymorphisms significantly increases the risk of nephropathy in type 2 diabetic patients of Asian Indian origin. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
44. Reversal of pancytopenia following kidney transplantation in a patient of primary hyperoxaluria with bone marrow involvement.
- Author
-
Sud, Kamal, Swaminathan, Sundararaman, Varma, Neelam, Kohli, Harbir Singh, Jha, Vivekanand, Gupta, Krishan Lal, and Sakhuja, Vinay
- Subjects
- *
KIDNEY diseases , *LIVER transplantation , *KIDNEY transplantation , *BONE marrow , *ENZYMES , *SEEPAGE - Abstract
Combined liver and kidney transplantation is the ideal treatment for patients with end-stage renal failure secondary to primary hyperoxaluria and systemic oxalosis, with a functioning liver providing replacement of the deficient enzyme and a functioning kidney providing the route of excretion for the oxalate crystals. Pancytopenia from bone marrow infiltration of oxalate crystals is a rare complication of primary hyperoxaluria, and its reversal following transplant has not been described. We report the first case of pancytopenia from marrow infiltration by oxalate crystals reversing following a successful kidney transplant alone. Although kidney alone transplants do not provide the best chance of survival or quality of life as compared to a combined kidney and liver transplant, a well functioning kidney transplant is able to take care of the systemic oxalate load and ameliorate, at least for a period of time, the systemic complications of oxalosis. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
45. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
- Author
-
Gauckler, Philipp, Shin, Jae Il, Alberici, Federico, Audard, Vincent, Bruchfeld, Annette, Busch, Martin, Cheung, Chee Kay, Crnogorac, Matija, Delbarba, Elisa, Eller, Kathrin, Faguer, Stanislas, Galesic, Kresimir, Griffin, Siân, Hrušková, Zdenka, Jeyabalan, Anushya, Karras, Alexandre, King, Catherine, Kohli, Harbir Singh, Maas, Rutger, and Mayer, Gert
- Subjects
- *
FOCAL segmental glomerulosclerosis , *RITUXIMAB , *IMMUNOSUPPRESSIVE agents , *MONOCLONAL antibodies , *NEPHROTIC syndrome , *DRUG side effects - Abstract
Primary forms of minimal change disease and focal segmental glomerulosclerosis are rare podocytopathies and clinically characterized by nephrotic syndrome. Glucocorticoids are the cornerstone of the initial immunosuppressive treatment in these two entities. Especially among adults with minimal change disease or focal segmental glomerulosclerosis, relapses, steroid dependence or resistance are common and necessitate re-initiation of steroids and other immunosuppressants. Effective steroid-sparing therapies and introduction of less toxic immunosuppressive agents are urgently needed to reduce undesirable side effects, in particular for patients whose disease course is complex. Rituximab, a B cell depleting monoclonal antibody, is increasingly used off-label in these circumstances, despite a low level of evidence for adult patients. Hence, critical questions concerning drug-safety, long-term efficacy and the optimal regimen for rituximab-treatment remain unanswered. Evidence in the form of large, multicenter studies and randomized controlled trials are urgently needed to overcome these limitations. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
46. COVID‐19 pandemic in limited‐resource countries: Strategies for challenges in a dialysis unit.
- Author
-
Bharati, Joyita, Ramachandran, Raja, Kumar, Vivek, and Kohli, Harbir Singh
- Subjects
- *
COVID-19 pandemic , *SARS-CoV-2 , *COVID-19 , *PERSONAL protective equipment , *HEALTH risk assessment - Published
- 2020
- Full Text
- View/download PDF
47. Role of Tacrolimus only therapy in modified Ponticelli regimen resistant idiopathic membranous glomerulonephritis.
- Author
-
Ramachandran, Raja, Sharma, Vinod, Nada, Ritambhra, Jha, Vivekanand, Gupta, Krishan Lal, and Kohli, Harbir Singh
- Subjects
- *
NEPHROTIC syndrome , *TACROLIMUS , *GLOMERULONEPHRITIS , *CALCINEURIN , *DRUG side effects , *PATIENTS - Abstract
The article discusses a study that aims to assess the role of Tacrolimus (TAC) only therapy in patients of nephrotic syndrome due to idiopathic membranous glomerulonephritis (IMGN)-resistant to modified Ponticelli regimen (MPR2). Calcineurin inhibitors (CNIs) have been used in IMGN. TAC is effective in a minority of patients with MPR-resistant IMGN and is associated with significant side-effects as concluded.
- Published
- 2015
- Full Text
- View/download PDF
48. A rare case of Cytomegalovirus, Scedosporium apiospermum and Mycobacterium tuberculosis in a renal transplant recipient.
- Author
-
Rathi, Manish, Gundlapalli, Srikant, Ramachandran, Raja, Mohindra, Sandeep, Kaur, Harsimran, Kumar, Vivek, Kohli, Harbir Singh, Gupta, Krishan Lal, and Sakhuja, Vinay
- Abstract
Background: Renal transplant recipients are at high risk of developing multiple infections, often concomitantly because of their immunocompromised status. Post renal transplant infections are often elusive and require extensive evaluation for proper diagnosis and treatment. A high index of suspicion is required and an attempt should be made to confirm the microbiological diagnosis from each site involved to rule out multiple infections.Case Presentation: We report a 50-year-old female, a renal allograft recipient who presented with left hemiplegia, esophageal ulcers and fever 3 months after her transplant. Esophageal biopsy revealed Cytomegalovirus (CMV) inclusions and the whole blood quantitative CMV polymerase chain reaction (PCR) was positive. Neuroimaging showed a brain abscess, stereotactic biopsy from which revealed Scedosporium apiospermum on fungal culture. Her tacrolimus and mycophenolate were stopped and she was managed with intravenous ganciclovir and voriconazole. With these measures, she showed marked improvement in her general and neurological condition. Two months later, she developed recurrence of fever with dry cough. Radiological investigation revealed a cavitating lung lesion, a needle aspiration from which demonstrated acid-fast bacilli. She was started on antituberculous treatment. With these measures, she recovered completely and maintained good graft function despite being on only prednisolone 10 mg once a day.Conclusion: Although CMV disease is not uncommon in the first three months post transplant, Scedosporium is a rare cause of brain abscess. On the other hand, tuberculosis is common in transplant recipients, especially in developing countries, like India. However, this is the first case report of occurrence of these three infections in the same patient, demonstrating the importance of a good microbiological work-up from each site involved in immunosuppressed subjects. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.